Walpar Nutritions Peer Comparison

Snapshot Summary

Walpar Nutritions Ltd. demonstrates impressive growth metrics, particularly in revenue and earnings, positioning it favorably compared to its peers. However, its valuation ratios suggest caution, as the company is still in the early stages of profitability. While several peers exhibit strong performance, some are overvalued based on their earnings potential, making Walpar a potential value pick within the sector.

• Walpar shows the highest revenue growth (YoY) at 77.91%.
• Cipla leads in profitability with the highest ROE of 16.63%.
• Sun Pharma has the highest PE ratio at 87.59, indicating overvaluation.
• Divi's Labs shows concerning revenue declines over 3 years, highlighting potential instability.

• Cipla Ltd.: Highest ROE of 16.63%, indicating effective management and strong profitability.
• Dr. Reddy's Laboratories Ltd.: Consistently strong growth with a solid balance sheet and good margins.
• Mankind Pharma Ltd.: Excellent revenue growth (YoY) with high profitability ratios.

Stock	CMP	Market Cap	P/E	ROE (%)	ROCE (%)	Debt/Equity
WALPAR	₹44.00	₹41.32Cr	17.78	15.05%	14.23%	0.59
SUNPHARMA	₹1,706.40	₹4,09,626.46Cr	39.49	16.16%	19.89%	0.03
DIVISLAB	₹6,804.00	₹1,80,668.62Cr	78.35	15.35%	20.45%	0.00
TORNTPHARM	₹3,628.30	₹1,20,456.12Cr	60.17	26.46%	27.32%	0.40
CIPLA	₹1,511.50	₹1,22,102.70Cr	22.44	16.63%	22.77%	0.01
DRREDDY	₹1,196.00	₹99,965.86Cr	17.32	18.61%	23.25%	0.14
ZYDUSLIFE	₹981.05	₹98,057.50Cr	21.45	21.08%	26.06%	0.13

Explore

Watchlists

Command Palette

Walpar Nutritions Peer Comparison

Snapshot Summary